437 related articles for article (PubMed ID: 12829921)
1. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients.
Teppo AM; Törnroth T; Honkanen E; Grönhagen-Riska C
Transplantation; 2003 Jun; 75(12):2113-9. PubMed ID: 12829921
[TBL] [Abstract][Full Text] [Related]
2. Urinary Type III Procollagen Is Associated With Chronic Allograft Dysfunction and Predicts Graft Survival.
Yılmaz R; Yıldırım T; Baydar DE; Altun B; Erdem Y
Transplant Proc; 2017 Mar; 49(2):281-287. PubMed ID: 28219585
[TBL] [Abstract][Full Text] [Related]
3. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
4. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance.
Quilliot D; Alla F; Böhme P; Bruntz JF; Hammadi M; Dousset B; Ziegler O; Zannad F
Int J Obes (Lond); 2005 Nov; 29(11):1321-8. PubMed ID: 16116494
[TBL] [Abstract][Full Text] [Related]
5. Tubular and glomerular function in children after renal transplantation.
Dagan A; Eisenstein B; Bar-Nathan N; Cleper R; Krause I; Smolkin V; Davidovits M
Pediatr Transplant; 2005 Aug; 9(4):440-4. PubMed ID: 16048594
[TBL] [Abstract][Full Text] [Related]
6. Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist.
Ghoul BE; Squalli T; Servais A; Elie C; Meas-Yedid V; Trivint C; Vanmassenhove J; Grünfeld JP; Olivo-Marin JC; Thervet E; Noël LH; Prié D; Fakhouri F
Clin J Am Soc Nephrol; 2010 Feb; 5(2):205-10. PubMed ID: 20089486
[TBL] [Abstract][Full Text] [Related]
7. Aminoterminal propeptide of type III procollagen: a marker of hepatic fibrosis after bile duct obstruction in the monkey.
Ruf G; Mappes HJ; Koch H; Baumgartner U; Hagmann W; Farthmann EH
Hepatogastroenterology; 1996; 43(7):121-6. PubMed ID: 8682446
[TBL] [Abstract][Full Text] [Related]
8. The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology.
Jensen LT
Dan Med Bull; 1997 Feb; 44(1):70-8. PubMed ID: 9062765
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta 1 in renal allograft recipients.
Coupes BM; Newstead CG; Short CD; Brenchley PE
Transplantation; 1994 Jun; 57(12):1727-31. PubMed ID: 8016876
[TBL] [Abstract][Full Text] [Related]
10. Urinary and serum type III collagen: markers of renal fibrosis.
Soylemezoglu O; Wild G; Dalley AJ; MacNeil S; Milford-Ward A; Brown CB; el Nahas AM
Nephrol Dial Transplant; 1997 Sep; 12(9):1883-9. PubMed ID: 9306339
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
12. Messenger RNA expression of target genes in the urinary sediment of patients with chronic kidney diseases.
Szeto CC; Chan RW; Lai KB; Szeto CY; Chow KM; Li PK; Lai FM
Nephrol Dial Transplant; 2005 Jan; 20(1):105-13. PubMed ID: 15561743
[TBL] [Abstract][Full Text] [Related]
13. [Hyaluronic acid and N-terminal procollagen-III-peptide in the urine in inflammatory and degenerative joint diseases].
Respondek M; Seibel MJ; Lautenschläger J; Müller W
Z Rheumatol; 1989; 48(3):117-22. PubMed ID: 2789456
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
15. Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: a new tool for predicting long-term graft function.
Pape L; Henne T; Offner G; Strehlau J; Ehrich JH; Mengel M; Grimm PC
Transplantation; 2003 Sep; 76(6):955-8. PubMed ID: 14508360
[TBL] [Abstract][Full Text] [Related]
16. Biochemical markers of types I and III collagen and limited joint mobility in type 1 diabetic patients.
Arkkila PE; Koskinen PJ; Kantola IM; Rönnemaa T; Seppänen E; Viikari JS
Acta Diabetol; 2003 Dec; 40(4):151-5. PubMed ID: 14740273
[TBL] [Abstract][Full Text] [Related]
17. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome.
Sciarretta S; Ferrucci A; Ciavarella GM; De Paolis P; Venturelli V; Tocci G; De Biase L; Rubattu S; Volpe M
Am J Hypertens; 2007 Jul; 20(7):784-91. PubMed ID: 17586414
[TBL] [Abstract][Full Text] [Related]
18. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
[TBL] [Abstract][Full Text] [Related]
19. Urinary excretion rates of multiple renal indicators after kidney transplantation: clinical significance for early graft outcome.
Matteucci E; Carmellini M; Bertoni C; Boldrini E; Mosca F; Giampietro O
Ren Fail; 1998 Mar; 20(2):325-30. PubMed ID: 9574459
[TBL] [Abstract][Full Text] [Related]
20. Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathy.
Timonen P; Magga J; Risteli J; Punnonen K; Vanninen E; Turpeinen A; Tuomainen P; Kuusisto J; Vuolteenaho O; Peuhkurinen K
Int J Cardiol; 2008 Mar; 124(3):293-300. PubMed ID: 17442428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
